| |
G/G (n=90)
|
G/A (n=106)
|
A/A (n=27)
|
P valuea
|
|---|
|
Age
|
46.61±10.14 (29.25-74.55)
|
49.98±10.24 (29.87-74.57)
|
47.83±9.81 (29.25-67.91)
|
0.067
|
|
BMIb
|
23.47±4.14 (15.06-34.48)
|
23.03±4.16 (2.25-38.05)
|
23.77±3.83 (18.18-32.05)
|
0.654
|
|
Tumor type
|
|
Infiltrating ductal carcinoma
|
73 (81.11%)
|
97 (91.51%)
|
23 (85.19%)
|
0.332
|
|
Ductal carcinoma in situ
|
10 (11.11%)
|
5 (4.72%)
|
2 (7.41%)
|
|
Others
|
5 (5.56%)
|
4 (3.77%)
|
2 (7.41%)
|
|
Unknown
|
2 (2.22%)
|
0 (0.00%)
|
0 (0.00%)
|
|
Side
|
|
Right
|
35 (38.89%)
|
52 (49.06%)
|
13 (48.15%)
|
0.704
|
|
Left
|
51 (56.67%)
|
50 (47.17%)
|
13 (48.15%)
|
|
Bilateral
|
4 (4.44%)
|
4 (3.77%)
|
1 (3.70%)
|
|
Tumor size
|
|
<5cm
|
64 (71.11%)
|
76 (71.70%)
|
19 (70.37%)
|
0.227
|
|
≥5cm
|
6 (6.67%)
|
16 (15.09%)
|
4 (14.81%)
|
|
Unknown
|
20 (22.22%)
|
14 (13.21%)
|
4 (14.81%)
|
|
Lymph node involvement
|
|
Positive
|
22 (24.44%)
|
55 (51.89%)
|
13 (48.15%)
|
0.002
|
|
Negative
|
61 (67.78%)
|
46 (43.40%)
|
14 (51.85%)
|
|
Unknown
|
7 (7.78%)
|
5 (4.72%)
|
0 (0.00%)
|
|
TMN staging
|
|
Stages 0-2
|
63 (70.00%)
|
71 (66.98%)
|
20 (74.07%)
|
0.194
|
|
Stages >2
|
7 (7.78%)
|
19 (17.92%)
|
4 (14.81%)
|
|
Unknown
|
20 (22.22%)
|
16 (15.09%)
|
3 (11.11%)
|
|
ER/PR status
|
|
Single or double positive
|
63 (70.00%)
|
68 (64.15%))
|
13 (48.15%)
|
0.006
|
|
Negative
|
13 (14.44%)
|
26 (24.53%)
|
13 (48.15%)
|
|
Unknown
|
14 (15.56%)
|
12 (11.32%)
|
1 (3.70%)
|
|
Family history
|
|
Positive
|
4 (4.44%)
|
3 (2.83%)
|
(0.00%)
|
0.823
|
|
Negative
|
81 (90.00%)
|
97 (91.51%)
|
25 (92.59%)
|
|
Unknown
|
5 (5.56%)
|
6 (5.66%)
|
2 (7.41%)
|
- NOTE: Data shown represent number of patients (% of n) or mean±s.d.. Bold type indicates p<0.050.
-
a, results of Chi-squared analysis or ANOVA test, depending on the type of parameter analyzed.
-
b, results from 185 patients.
- Abbreviations: ER estrogen receptor, PR progesterone receptor.
